6 results about "Aedes aegypti" patented technology

The application provides a dengue virus protection and mosquito vector control antigen composition and application thereof. The antigen composition comprises a combination of dengue virus type 1-4 envelope protein domain III polypeptide and Aedes aegypti midgut mucin AaMuc1 antigen polypeptide; the amino acid sequences of the dengue virus type 1-4 envelope protein domain III polypeptide are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4; and the amino acid sequence of the Aedes aegypti midgut mucin AaMuc1 antigen polypeptide is shown as SEQ ID NO. 5. The prepared vaccine can induce the body to produce neutralizing antibodies against dengue virus type 1-4, achieve the protection of human body from dengue virus infection, induce the production of active antibodies targeting Aedes aegypti midgut mucin 1, inhibit and kill the dengue virus transmission vector Aedes aegypti, and achieve the dual prevention and control of dengue fever from two dimensions of infection prevention and transmission interruption.

The invention discloses a composite insecticide targeting aedes aegypti PGRP gene and application thereof, the insecticide is a preparation taking double-stranded RNA of a key PGRP gene as an effective component, and the double-stranded RNA comprises a gene aiming at PGRP-LB subtype and coding dsPGRP-LB and a gene aiming at PGRP-SC2 subtype and coding dsPGRP-SC2; wherein the nucleotide sequence of a front primer of the gene for coding the dsPGRP-LB is as shown in SEQ ID NO. 1; the nucleotide sequence of a rear primer for coding the gene dsPGRP-LB is as shown in SEQ ID NO. 2; the nucleotide sequence of a front primer for coding the gene dsPGRP-SC2 is as shown in SEQ ID NO. 3; and the nucleotide sequence of a rear primer of the gene for coding the dsPGRP-SC2 is as shown in SEQ ID NO. 4. According to the invention, the target specificity is strong, non-target biological interference is avoided, the insecticidal efficiency is obviously improved, the synergistic increasing agent has good suitability, mistaken killing of beneficial organisms in an ecological system is avoided, and accurate mosquito control is realized.

This invention discloses a TOR inhibitor and its application in inhibiting mosquito cell proliferation, relating to the field of pesticides. The TOR inhibitor is at least one of RAP, AZD-8055, and JR-AB2-011. Using three complementary TOR inhibitors—RAP, AZD-8055, and JR-AB2-011—at the embryonic cell level of Aedes aegypti Aag2 mosquitoes, the TOR signaling pathway was confirmed to be a key target regulating cell proliferation. This target is novel, with a clear mechanism, and is completely different from traditional insecticide pathways. The three inhibitors showed significant and dose-dependent inhibitory effects in vitro, possessing the potential to reduce the risk of drug resistance. At the same time, they have minimal impact on non-target organisms and are highly environmentally friendly. This provides experimental and theoretical support for the development of novel, highly effective, and low-risk mosquito repellent agents, and has important potential application value for the control of Aedes aegypti and the blocking of vector-borne infectious diseases.

The invention relates to an insecticidal varnish composed of a colourless, water-based acrylic copolymer with a satin finish and very low odour, the aqueous formulation of which contains microcapsules of lambda-cyhalothrin (C23H19ClF3NO3 - alpha-cyano-3-phenoxybenzyl-3-(2-chloro-3,3,3-trifluoropropenyl)-2,2-dimethylcyclopropanecarboxylate) in concentrations ranging from 0.001% w / w to a permitted maximum of 10% w / w, which, when broken by mechanical contact, release the insecticide slowly, gradually and safely, making the surface lethal to insects, with mortality efficacy levels of 100% in 24 hours for the dengue mosquito (Aedes aegypt) and 82.5% in 72 hours for cockroaches (Periplaneta americana).

The invention discloses a benzimidazole salt compound with insecticidal activity as well as a preparation method and application thereof, and aims to solve the problem that an existing insecticide cannot give consideration to insecticidal activity and resistance at the same time. The salt compound containing the benzimidazole structure provided by the invention has good insecticidal activity on aedes aegypti, mythimna orientalis and plutella xylostella, has no cross resistance or obvious negative cross resistance on aedes aegypti pyrethroid-resistant strains, and has the control effect on the plutella xylostella equivalent to that of commercial insecticide permethrin sold in the market. A lead compound with application potential and an innovative research and development thought are provided for creating novel resistance treatment pesticides with negative cross resistance characteristics.

The application discloses an arecoline ester derivative, a preparation method and application thereof, relates to the technical field of chemical pesticides, and has a brand-new molecular structure, and the bacteriostatic activity and insecticidal activity of the arecoline ester derivative are significantly enhanced compared with arecoline; the arecoline ester derivative has certain inhibiting effects on Puccinia recondita, Diplodia natalensis, Gibberella saubinetii, Pyricularia grisea, Phomopsis vexans, Physalospora piricola, Pestalotiopsis versiflorea, and Colletotrichum gloeosporioides; and the arecoline ester derivative also has certain insecticidal activity on Aedes aegypti larvae.